Leukemia drug duration under microscope in new mayo study

NCT ID NCT07221656

Not yet recruiting Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 28 times

Summary

This study looks at how long the drug calaspargase pegol stays active in the blood of children with acute lymphoblastic leukemia or lymphoma. Researchers want to know if higher drug levels are linked to more side effects. About 20 children will take part, and the goal is to better understand the drug's behavior to improve future treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.